BioNTech (BNTX) vs Repligen (RGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Repligen (RGEN) has outperformed BioNTech (BNTX) over the past year, gaining 14.6% versus a loss of 10.2%. Over five years, RGEN leads with a -37.4% price change compared with -61.5% for BNTX. BioNTech is the larger company by market cap ($23.13 billion vs $10.40 billion), about 2.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | RGEN |
|---|---|---|
| Share price | $92.06 | $163.84 |
| Market cap | $23.13B | $10.40B |
| 1-day change | -3.35% | -2.02% |
| YTD return | +0.05% | +2.05% |
| 1-year return | -10.19% | +14.59% |
| 5-year return | -61.54% | -37.35% |
| P/E ratio (TTM) | — | 224.44 |
| Forward P/E | — | 61.84 |
| EPS (TTM) | $-7.83 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $738.26M |
| Revenue growth (YoY) | — | +16.36% |
| Net income (latest FY) | — | $48.89M |
| Gross margin | — | 52.32% |
| Operating margin | — | 7.47% |
| Net margin | — | 6.62% |
| 52-week high | $124.00 | $198.87 |
| 52-week low | $79.52 | $100.99 |
| Distance from 52-week high | -25.76% | -17.61% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +25.78% | +18.99% |
| Average volume | 1.15M | 1.17M |
| Shares outstanding | 251.20M | 63.49M |
| Employees | 7,807 | 2,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BioNTech is about 2.2 times larger than Repligen by market value ($23.13B vs $10.40B).
- RGEN has outperformed BNTX by 24.8 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Repligen
RGEN stock →Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,000 employees
BNTX vs RGEN FAQ
Which is bigger, BioNTech or Repligen?
BioNTech (BNTX) is larger, with a market capitalization of $23.13B compared with $10.40B for Repligen (RGEN).
Which stock has performed better over the past year, BNTX or RGEN?
RGEN returned +14.59% over the past 12 months, compared with -10.19% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are BioNTech and Repligen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.